Summary of significant accounting policies (Tables)
|
12 Months Ended |
Jul. 31, 2015 |
Accounting Policies [Abstract] |
|
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block] |
The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category:
|
|
Years Ended July 31, |
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Revenue category |
|
Amount |
|
|
% |
|
|
Amount |
|
|
% |
|
|
Amount |
|
|
% |
|
Third-party payers |
|
$ |
35,631 |
|
|
|
56 |
|
|
$ |
29,509 |
|
|
|
50 |
|
|
$ |
26,014 |
|
|
|
47 |
|
Medicare |
|
|
11,981 |
|
|
|
19 |
|
|
|
12,815 |
|
|
|
22 |
|
|
|
12,497 |
|
|
|
22 |
|
Patient self-pay |
|
|
11,028 |
|
|
|
17 |
|
|
|
11,204 |
|
|
|
19 |
|
|
|
12,172 |
|
|
|
22 |
|
HMO’s |
|
|
4,774 |
|
|
|
8 |
|
|
|
5,161 |
|
|
|
9 |
|
|
|
5,206 |
|
|
|
9 |
|
Total |
|
$ |
63,414 |
|
|
|
100 |
% |
|
$ |
58,689 |
|
|
|
100 |
% |
|
$ |
55,889 |
|
|
|
100 |
% |
|
Schedule Of Accounts Receivable By Segment [Table Text Block] |
The following is a table of the Company’s net accounts receivable by segment.
|
|
July 31, 2015 |
|
|
July 31, 2014 |
|
Net accounts receivable by segment |
|
Amount |
|
|
% |
|
|
Amount |
|
|
% |
|
Clinical Labs (by billing category) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third party payers |
|
$ |
3,595 |
|
|
|
44 |
|
|
$ |
3,499 |
|
|
|
46 |
|
Patient self-pay |
|
|
3,213 |
|
|
|
39 |
|
|
|
2,193 |
|
|
|
29 |
|
Medicare |
|
|
1,081 |
|
|
|
13 |
|
|
|
1,558 |
|
|
|
21 |
|
HMO’s |
|
|
305 |
|
|
|
4 |
|
|
|
280 |
|
|
|
4 |
|
Total Clinical Labs |
|
|
8,194 |
|
|
|
100 |
% |
|
|
7,530 |
|
|
|
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Life Sciences |
|
|
3,915 |
|
|
|
|
|
|
|
4,940 |
|
|
|
|
|
Total accounts receivable – net |
|
$ |
12,109 |
|
|
|
|
|
|
$ |
12,470 |
|
|
|
|
|
|
Schedule of Allowance for Doubtful Accounts Receivable [Table Text Block] |
Changes in the Company’s allowance for doubtful accounts are as follows:
|
|
July 31, 2015 |
|
|
July 31, 2014 |
|
Beginning balance |
|
$ |
2,142 |
|
|
$ |
2,707 |
|
Provision for doubtful accounts |
|
|
2,284 |
|
|
|
3,063 |
|
Write-offs |
|
|
(2,640 |
) |
|
|
(3,628 |
) |
Ending balance |
|
$ |
1,786 |
|
|
$ |
2,142 |
|
|
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] |
The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31:
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Net loss |
|
$ |
(2,285 |
) |
|
$ |
(9,977 |
) |
|
$ |
(18,237 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding - basic |
|
|
45,355 |
|
|
|
42,561 |
|
|
|
39,607 |
|
Add: effect of dilutive stock options and restricted stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
Weighted-average common shares outstanding - diluted |
|
|
45,355 |
|
|
|
42,561 |
|
|
|
39,607 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share – basic and diluted |
|
$ |
(0.05 |
) |
|
$ |
(0.23 |
) |
|
$ |
(0.46 |
) |
|
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] |
The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31:
|
|
2015 |
|
|
2014 |
|
|
2013 |
|
Cost of clinical laboratory services |
|
$ |
5 |
|
|
$ |
9 |
|
|
$ |
10 |
|
Research and development |
|
|
2 |
|
|
|
1 |
|
|
|
2 |
|
Selling, general and administrative |
|
|
422 |
|
|
|
584 |
|
|
|
533 |
|
|
|
$ |
429 |
|
|
$ |
594 |
|
|
$ |
545 |
|
|